



2025 Q3 Results

Asymchem Laboratories (Tianjin) Co., Ltd.

002821.SZ/6821.HK

This document is not for public dissemination and the information contained herein is for the exclusive use of the persons to whom it is addressed and their advisers in connection with Asymchem Laboratories (Tianjin) Co., Ltd. (the “**Company**”, together with its subsidiaries, hereinafter referred to as the “**Group**”). It is being made available by the Company to a limited number of recipients. The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and whoever comes into possession of this document should inform themselves about, and observe such restrictions. Any failure to comply with this restriction may constitute a violation of the United States, Canadian, PRC or Japanese securities laws or the laws of any such other jurisdictions. By accepting this document, you agree to be bound by the foregoing limitations.

Forward-Looking Statement

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

All financials disclosed in this document are presented in accordance with International Financial Reporting Standards (“**IFRS**”s) except for those specifically noted otherwise.

Use of Adjusted Financial Measures

We have provided adjusted net profit attributable to shareholders of the Company and adjusted net profit margin attributable to shareholders of the Company as additional financial measures, which are not required by, or presented in accordance with, the IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of these non- IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS.

4,630

Revenue (RMB mm)

 +13.2%

42.2%

Gross Profit Margin

(0.7pts²)

800

Net Profit Attributable to
Shareholders of the Company
(RMB mm)

 +12.7%

17.3%

Net Profit Margin
Attributable to Shareholders
of the Company

(0.1pts)

Small Molecule CDMO Business

Revenue

Remaining
Almost Flat

Gross Profit Margin

46.8%

Emerging Business

Revenue

 72.2%

Gross Profit Margin


30.3%

The Revenue from chemical macromolecule business soared by **over 150%** yoy³
The gross profit margin of the emerging business increased by **10.5 pts**


Supported by the growth business segments such as peptides, oligonucleotides and ADCs, the Company continued its market expansion.
The total value of newly signed orders sustained **double-digit growth**.

Based on the distribution of orders scheduled for delivery in 2025H2, the delivery volume in Q4 is expected to be significantly higher than that in the Q3.
The Company anticipates to achieve a revenue growth of **13% -15%** for the full year.


Revenue From Large Pharma
(Exclude Large Orders)




Revenue From Small-to-Mid Pharma




Selling and Distribution Expenses as % of Total Revenue



Administrative Expenses* as % of Total Revenue




R&D Expenses as % of Total Revenue




Finance Costs* as % of Total Revenue

2024Q1-Q3



*Due to the disparities between Chinese Accounting Standards ("CAS") and International Financial Reporting Standards ("IFRS"), there exist variations in the treatment of administrative expenses and finance costs. Consequently, under IFRS, these expenses differ from those recognized under CAS. To accurately represent the concept of "net finance costs," we have chosen to utilize finance costs as per CAS. This entails including exchange gains, bank interest income, bank charges, and other expenses/gains derived from financing activities.



Appendix



CONSOLIDATED STATEMENT OF PROFIT OR LOSS

RMB mm

	2025 Q1-Q3	2024 Q1-Q3
Revenue	4,630	4,091
Cost of sales	(2,675)	(2,335)
Gross profit	1,955	1,756
Other income and gains	266	263
Selling and distribution expenses	(150)	(167)
Administrative expenses	(609)	(558)
Research and development expenses	(433)	(484)
Net impairment losses on financial and contract assets	(36)	(10)
Other expenses	(77)	(28)
Finance costs	(9)	(4)
Share of profit/(loss) of associate	3	(9)
Profit before tax	910	759
Income tax expense	(118)	(59)
Profit for the period	792	700
Attributable to:		
Owners of the parent	800	710
Non-controlling interests	(8)	(10)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

RMB mm

	2025 Q3	2024
Non-current assets		
Property, plant and equipment	6,214	5,940
Right-of-use assets	628	700
Goodwill	146	146
Other intangible assets	72	27
Deferred tax assets	283	248
Investments in associates	540	537
Prepayments, deposits and other receivables	378	483
Financial assets at fair value through profit or loss	176	158
Total non-current assets	8,437	8,239
current assets		
Inventories	1,497	1,193
Trade receivables	1,536	1,837
Contract assets	93	102
Prepayments, deposits and other receivables	682	587
Tax recoverable	1	2
Financial assets at fair value through profit or loss	899	1,540
Cash and bank balances	6,662	5,789
Total current assets	11,370	11,050
Total assets	19,807	19,289

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(continued)

RMB mm

	2025 Q3	2024
Current liabilities		
Trade payables	580	451
Other payables and accruals	1,125	1,166
Lease liabilities	51	42
Tax payable	28	50
Total current liabilities	1,784	1,709
Non-current liabilities		
Deferred income	274	299
Lease liabilities	267	283
Deferred tax liabilities	121	135
Total non-current liabilities	663	717
Equity		
Share capital	361	368
Treasury shares	(422)	(1,232)
Other reserves	17,411	17,710
Non-controlling interests	10	17
Total equity	17,360	16,863



Thanks!

